CL2017003475A1 - Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona - Google Patents

Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona

Info

Publication number
CL2017003475A1
CL2017003475A1 CL2017003475A CL2017003475A CL2017003475A1 CL 2017003475 A1 CL2017003475 A1 CL 2017003475A1 CL 2017003475 A CL2017003475 A CL 2017003475A CL 2017003475 A CL2017003475 A CL 2017003475A CL 2017003475 A1 CL2017003475 A1 CL 2017003475A1
Authority
CL
Chile
Prior art keywords
azetidin
piperidin
difluoro
fluoro
fumarate salt
Prior art date
Application number
CL2017003475A
Other languages
English (en)
Inventor
Adrian St Clair Brown
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56411938&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2017003475(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of CL2017003475A1 publication Critical patent/CL2017003475A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

<p>LA PRESENTE DESCRIPCIÓN SE REFIERE A LA SAL DE FUMARATO CRISTALINA DE (S)-[3,4-DIFLUORO-2-(2-FLUORO-4-YODOFENILAMINO)FENIL][3- HIDROXI-3-(PIPERIDIN-2-IL)AZETIDIN-1-IL]-METANONA. LA DESCRIPCIÓN TAMBIÉN SE REFIERE A COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN LA SAL DE FUMARATO CRISTALINA DE (S)-[3,4-DIFLUORO-2-(2-FLUORO-4-YODOFENILAMINO)FENIL][3-HIDROXI-3-(PIPERIDIN-2-IL) AZETIDIN-1-IL]-METANONA. LA DESCRIPCIÓN TAMBIÉN SE REFIERE A MÉTODOS PARA TRATAR CÁNCERES QUE COMPRENDEN ADMINISTRARLE A UN PACIENTE QUE LO NECESITA LA SAL DE FUMARATO CRISTALINA DE (S)-[3,4-DIFLUORO-2-(2-FLUORO-4-YODOFENILAMINO)FENIL][3-HIDROXI-3- (PIPERIDIN-2-IL)AZETIDIN-1-IL]-METANONA.</p>
CL2017003475A 2015-06-30 2017-12-29 Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona CL2017003475A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562187009P 2015-06-30 2015-06-30

Publications (1)

Publication Number Publication Date
CL2017003475A1 true CL2017003475A1 (es) 2018-07-13

Family

ID=56411938

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017003475A CL2017003475A1 (es) 2015-06-30 2017-12-29 Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona

Country Status (35)

Country Link
US (3) US10590102B2 (es)
EP (1) EP3317264B1 (es)
JP (3) JP7338950B2 (es)
KR (1) KR102695324B1 (es)
CN (2) CN107810183A (es)
AR (1) AR105483A1 (es)
AU (2) AU2016288209B2 (es)
CA (1) CA2990222C (es)
CL (1) CL2017003475A1 (es)
CO (1) CO2018000086A2 (es)
CR (1) CR20180056A (es)
DK (1) DK3317264T3 (es)
ES (1) ES3058194T3 (es)
FI (1) FI3317264T3 (es)
HK (1) HK1252433A1 (es)
HR (1) HRP20251507T1 (es)
IL (2) IL295052A (es)
LT (1) LT3317264T (es)
MA (1) MA42301B1 (es)
MD (1) MD3317264T2 (es)
MX (1) MX390250B (es)
MY (1) MY192545A (es)
PE (1) PE20180692A1 (es)
PH (1) PH12017502414A1 (es)
PL (1) PL3317264T3 (es)
PT (1) PT3317264T (es)
RS (1) RS67509B1 (es)
RU (2) RU2021132394A (es)
SG (1) SG10202105196YA (es)
SI (1) SI3317264T1 (es)
SM (1) SMT202500458T1 (es)
TW (2) TWI775187B (es)
UA (1) UA124728C2 (es)
WO (1) WO2017004393A1 (es)
ZA (1) ZA201708760B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2909188T1 (en) 2012-10-12 2018-07-31 Exelixis, Inc. A novel process for the manufacture of compounds for use in the treatment of cancer
TWI804919B (zh) * 2015-06-30 2023-06-11 美商建南德克公司 含藥物之立即釋放錠劑及形成該錠劑的方法
AR105483A1 (es) 2015-06-30 2017-10-11 Exelixis Inc Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
GB201717809D0 (en) * 2017-10-30 2017-12-13 Azad Pharmaceutical Ingredients Ag Process for the production of cobimetinib
WO2020187674A1 (en) 2019-03-15 2020-09-24 Sandoz Ag Crystalline (s)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl][3-hydroxy-3-(piperidin-2-yl)azetidin-1-yl]methanone hemisuccinate
AU2023384196A1 (en) * 2022-11-25 2025-06-12 Msn Laboratories Private Limited, R&D Center Crystalline forms of n-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide fumarate and process for its preparation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2444866T3 (es) 2004-10-20 2014-02-27 Merck Serono Sa Derivados de 3-arilamino piridina
EP2270000B1 (en) 2005-05-23 2015-07-29 Novartis AG Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts
NZ567140A (en) 2005-10-07 2011-09-30 Exelixis Inc Azetidines as MEK inhibitors for the treatment of proliferative diseases
CA2658725A1 (en) 2006-08-16 2008-02-21 Exelixis, Inc. Using pi3k and mek modulators in treatments of cancer
WO2008076415A1 (en) 2006-12-14 2008-06-26 Exelixis, Inc. Methods of using mek inhibitors
WO2008124085A2 (en) 2007-04-03 2008-10-16 Exelixis, Inc. Methods of using combinations of mek and jak-2 inhibitors
SI2909188T1 (en) 2012-10-12 2018-07-31 Exelixis, Inc. A novel process for the manufacture of compounds for use in the treatment of cancer
CN105163584B (zh) 2013-03-05 2019-06-04 田纳西大学研究基金会 用于治疗癌症的化合物
WO2014152358A2 (en) 2013-03-14 2014-09-25 Genentech, Inc. Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use
AR105483A1 (es) 2015-06-30 2017-10-11 Exelixis Inc Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona

Also Published As

Publication number Publication date
TWI710556B (zh) 2020-11-21
MD3317264T2 (ro) 2026-01-31
IL256423A (en) 2018-02-28
US20220056010A1 (en) 2022-02-24
EP3317264B1 (en) 2025-09-10
MA42301A (fr) 2018-05-09
US20200255398A1 (en) 2020-08-13
AU2021200202B2 (en) 2022-09-08
JP7338950B2 (ja) 2023-09-05
TWI775187B (zh) 2022-08-21
EP3317264A1 (en) 2018-05-09
PH12017502414A1 (en) 2018-06-25
CR20180056A (es) 2018-05-25
RU2018103172A3 (es) 2019-10-31
FI3317264T3 (fi) 2025-12-05
UA124728C2 (uk) 2021-11-10
PE20180692A1 (es) 2018-04-23
TW201718535A (zh) 2017-06-01
IL295052A (en) 2022-09-01
IL256423B (en) 2022-09-01
NZ777527A (en) 2024-10-25
HRP20251507T1 (hr) 2026-01-02
LT3317264T (lt) 2025-12-29
KR20180021775A (ko) 2018-03-05
MX2017017037A (es) 2018-04-30
PL3317264T3 (pl) 2026-02-16
BR112017028516A2 (pt) 2018-08-28
RS67509B1 (sr) 2025-12-31
TW202108568A (zh) 2021-03-01
CA2990222A1 (en) 2017-01-05
HK1252433A1 (zh) 2019-05-24
ZA201708760B (en) 2022-06-29
AU2016288209A1 (en) 2018-02-08
JP2023025000A (ja) 2023-02-21
US11254649B2 (en) 2022-02-22
US20180346442A1 (en) 2018-12-06
AU2016288209B2 (en) 2020-10-22
RU2762181C2 (ru) 2021-12-16
SMT202500458T1 (it) 2026-01-12
CO2018000086A2 (es) 2018-04-10
KR102695324B1 (ko) 2024-08-13
ES3058194T3 (en) 2026-03-09
SG10202105196YA (en) 2021-06-29
MA42301B1 (fr) 2025-12-31
AU2021200202A1 (en) 2021-03-18
SI3317264T1 (sl) 2026-01-30
WO2017004393A1 (en) 2017-01-05
MY192545A (en) 2022-08-26
JP2021035967A (ja) 2021-03-04
RU2021132394A (ru) 2021-11-18
DK3317264T3 (da) 2025-12-01
MX390250B (es) 2025-03-20
RU2018103172A (ru) 2019-07-31
CN118290395A (zh) 2024-07-05
CN107810183A (zh) 2018-03-16
AR105483A1 (es) 2017-10-11
PT3317264T (pt) 2025-12-12
JP2018519318A (ja) 2018-07-19
US10590102B2 (en) 2020-03-17
NZ739160A (en) 2024-10-25
CA2990222C (en) 2023-09-26

Similar Documents

Publication Publication Date Title
CO2018000086A2 (es) Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona
CY1123059T1 (el) Αναστολη του διαυλου ιοντων παροδικου δυναμικου του υποδοχεα α1
EA201790766A1 (ru) Новые соединения метилпиперидина, подходящие для ингибирования микросомальной простагландин-e2-синтазы 1
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
MX2021002382A (es) Sales y formas cristalinas de modulador alosterico positivo gabaa.
MX2018000396A (es) Compuestos aza sustituidos como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak-4).
EA201790764A1 (ru) Новые соединения карбоновых кислот, подходящие для ингибирования микросомальной простагландин-e2-синтазы 1
PH12017500639A1 (en) Neuroactive compounds and methods of use thereof
EA201591805A1 (ru) Оксабицикло [2.2.2] кислоты - модуляторы gpr120
MX2017001620A (es) Formas cristalinas de inhibidores de glutaminasa.
MX2016003823A (es) Inhibidor selectivo de fosfatidil-inositol 3-cinasa-gamma.
EA201790726A1 (ru) Фармацевтическая композиция для лечения язвенного колита
EA201790496A1 (ru) Соединения 1-алкил-6-оксо-1,6-дигидропиридин-3-ила и применение в качестве модуляторов sgrm
MX2016011105A (es) Inhibidores de monoacilglicerol aciltransferasa 2 (mgat2) de dihidropiridinona para usarse en el tratamiento de trastornos metabolicos.
CL2015002488A1 (es) Sal de abexinostato novedosa, forma cristalina relacionada, método de preparación de esta y las composiciones farmacéuticas que la contienen
PH12019500822B1 (en) Crystalline forms of eravacycline
MX2017004312A (es) Composicion farmaceutica oral de baja dosis de isotretinoina.
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
CL2016003155A1 (es) Composiciones de cuidado bucal
BR112018012325A2 (pt) métodos para a preparação de 5,6-di-hidro-6-fenilbenzo[f]isoquinolin-2-amina substituída
SG10201810263QA (en) Nampt inhibitors and methods
BR112017018192A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, e, composição farmacêutica.
PH12018500886A1 (en) Dibenzo azepine compounds and their use in the treatment of otic diseases and disorders
CY1124229T1 (el) Συνδυασμος τραζοδονης και γκαμπαπεντινης για την αντιμετωπιση του πονου
EA201690908A1 (ru) Пиразолопиримидиновые соединения